22 May 2017
This report focuses on key upcoming catalysts for private drug development companies across multiple indications.
Included in this report:
Investigative News
- Oncoceutics’ early glioblastoma data sparks expert support, while company explores strategic options
- Stealth’s Phase II mitochondrial disease extension trial spurs physician enthusiasm for elamipretide sustained efficacy, clinical significance uncertain
- Stealth BioTherapeutics’ planned Phase III trial divides physicians over potential elamipretide protocol length, functional endpoints desired
- Melinta’s delafloxacin Phase III efficacy data supports approval for ABSSSI, fluoroquinolonerelated side effects could blunt uptake – experts
- Protagonist’s PTG-100 has uncertain Phase IIb success forecasts in UC, possible infection concerns raised – experts
Data Analysis
- Number of Drug Candidates Currently in Clinical Development by Private Companies Split by the Region In Which the Company is Headquartered
- Largest Drug or Biologic Licensing Deals Involving a Private Company in 1Q17